How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
MacroGenics pays for its ASCO exuberance
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Merck matches Kelun’s saci-tirumo efforts
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
